Medtronic PLC Company Profile (NYSE:MDT)

About Medtronic PLC (NYSE:MDT)

Medtronic PLC logoMedtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:MDT
  • CUSIP: 58505510
  • Web:
  • Market Cap: $107.96089 billion
  • Outstanding Shares: 1,354,591,000
Average Prices:
  • 50 Day Moving Avg: $82.04
  • 200 Day Moving Avg: $83.67
  • 52 Week Range: $69.35 - $89.72
  • Trailing P/E Ratio: 26.83
  • Foreward P/E Ratio: 15.48
  • P/E Growth: 2.56
Sales & Book Value:
  • Annual Revenue: $29.93 billion
  • Price / Sales: 3.61
  • Book Value: $37.41 per share
  • Price / Book: 2.13
  • Annual Dividend: $1.84
  • Dividend Yield: 2.3%
  • EBIDTA: $9.19 billion
  • Net Margins: 13.75%
  • Return on Equity: 12.92%
  • Return on Assets: 6.56%
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 1.64%
  • Quick Ratio: 1.40%
  • Average Volume: 4.43 million shs.
  • Beta: 1.03
  • Short Ratio: 1.86

Frequently Asked Questions for Medtronic PLC (NYSE:MDT)

What is Medtronic PLC's stock symbol?

Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic PLC pay dividends? What is the dividend yield for Medtronic PLC?

Medtronic PLC declared a quarterly dividend on Monday, August 28th. Stockholders of record on Friday, September 29th will be given a dividend of $0.46 per share on Friday, October 20th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.31%. The ex-dividend date of this dividend is Thursday, September 28th. View Medtronic PLC's Dividend History.

How were Medtronic PLC's earnings last quarter?

Medtronic PLC (NYSE:MDT) announced its quarterly earnings data on Tuesday, August, 22nd. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.08 by $0.04. The business had revenue of $7.39 billion for the quarter, compared to analysts' expectations of $7.44 billion. Medtronic PLC had a net margin of 13.75% and a return on equity of 12.92%. Medtronic PLC's quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the firm posted $1.03 EPS. View Medtronic PLC's Earnings History.

When will Medtronic PLC make its next earnings announcement?

Medtronic PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Medtronic PLC.

Where is Medtronic PLC's stock going? Where will Medtronic PLC's stock price be in 2017?

21 brokerages have issued 12-month target prices for Medtronic PLC's stock. Their forecasts range from $78.00 to $96.00. On average, they anticipate Medtronic PLC's stock price to reach $88.82 in the next year. View Analyst Ratings for Medtronic PLC.

What are analysts saying about Medtronic PLC stock?

Here are some recent quotes from research analysts about Medtronic PLC stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Medtronic has been observed to underperform the broader industry. We note that, escalating costs and expenses are weighing on margins. Also, unfavorable foreign exchange continues to remain a drag. On a positive note,  we observe that apart from displaying successful integration and achievement of synergy targets, Medtronic’s major business groups continue to contribute to top-line growth which highlighted sustainability across all segments and geographies. Recently, the company announced the receipt of regulatory approval from the Japanese MHLW for its IN.PACT Admiral Drug-Coated Balloon. The stabilizing trend in the global Cardiac Rhythm & Heart Failure (CRHF) market is another upside. We are also encouraged by the solid growth trend, continuing in the U.S. as well as the healthy global acceptance of its advanced therapies." (9/12/2017)
  • 2. Needham & Company LLC analysts commented, "F4Q17 revenue and EPS beat consensus and initial FY18 guidance was in line with consensus. Organic revenue growth was steady at 4.0% vs. 4.1% in F3Q17 with new products adding ~370 bps, emerging markets adding ~125 bps and services & solutions adding ~15 bps. Operating margin was above consensus and up 10 bps Y/Y (or 40 bps Y/Y CC). MDT’s product cycle remains strong with significant FY18 launches including: the Resolute Onyx DES, MiniMed 670G insulin pump, Signia powered stapler, new LigaSure instruments, Intellis spinal cord stimulator, Evolut PRO TAVR, and MRI CRT-P quadripolar system." (5/25/2017)
  • 3. BTIG Research analysts commented, "At last Friday's American College of Cardiology (ACC) meeting, two-year data on MDT's SURTAVI trial for intermediate-risk was presented. At the two-year mark, all cause death/stroke were similar for TAVR using MDT's valves (12.6%) vs. surgery (14%) though use of TAVR reduced 30-day strokes, kidney injury, afib, and hospital stay. While we were surprised TAVR was not superior to surgery as in other trials, it seems surgical results improved. Still, TAVR is at least as good with less invasiveness. While not the same trials, investors have tried to compare MDT's CoreValve to Edwards' (EW, Neutral) SAPIEN 3 based on available data. At 1 year, all-cause death and stroke were equivalent at 8.1% for CoreValve and 8.4% for SAPIEN 3. Overall, patient selection (EW's intermediate risk pool may have had more comorbidities) and device design (MDT mainly used its older valve) make it tough to directly compare both trials; but we believe the valves are essentially equivalent and either one should be chosen over surgery." (3/20/2017)
  • 4. Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)

Who are some of Medtronic PLC's key competitors?

Who owns Medtronic PLC stock?

Medtronic PLC's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.71%), BlackRock Inc. (6.59%), State Street Corp (4.53%), FMR LLC (3.80%), Franklin Resources Inc. (2.81%) and Capital Research Global Investors (2.31%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz, Robert C Pozen and Shirley A Jackson. View Institutional Ownership Trends for Medtronic PLC.

Who sold Medtronic PLC stock? Who is selling Medtronic PLC stock?

Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Capital Research Global Investors, State Street Corp, Capital Guardian Trust Co., Dodge & Cox, Standard Life Investments LTD and Bank of New York Mellon Corp. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Hoedt Rob Ten, Hooman Hakami, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic PLC.

Who bought Medtronic PLC stock? Who is buying Medtronic PLC stock?

Medtronic PLC's stock was acquired by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., Vanguard Group Inc., Sanders Capital LLC, Principal Financial Group Inc., Koch Industries Inc. and American Century Companies Inc.. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic PLC.

How do I buy Medtronic PLC stock?

Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic PLC's stock price today?

One share of Medtronic PLC stock can currently be purchased for approximately $79.70.

MarketBeat Community Rating for Medtronic PLC (NYSE MDT)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  826 (Vote Outperform)
Underperform Votes:  530 (Vote Underperform)
Total Votes:  1,356
MarketBeat's community ratings are surveys of what our community members think about Medtronic PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Medtronic PLC (NYSE:MDT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $88.82 (11.45% upside)

Analysts' Ratings History for Medtronic PLC (NYSE:MDT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Jefferies Group LLCLower Price TargetBuy$103.00 -> $96.00LowView Rating Details
8/23/2017Barclays PLCLower Price TargetOverweight$94.00 -> $92.00LowView Rating Details
8/23/2017BMO Capital MarketsReiterated RatingOutperform$94.00 -> $92.00LowView Rating Details
8/22/2017Cowen and CompanySet Price TargetBuy$95.00LowView Rating Details
8/22/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$92.00MediumView Rating Details
8/21/2017Royal Bank Of CanadaReiterated RatingBuy$90.00LowView Rating Details
7/31/2017Deutsche Bank AGSet Price TargetBuy$96.00LowView Rating Details
7/12/2017Wells Fargo & CompanyReiterated RatingOutperformLowView Rating Details
7/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
5/30/2017Morgan StanleyBoost Price TargetEqual Weight$84.00 -> $86.00LowView Rating Details
5/28/2017Stifel NicolausReiterated RatingHold$84.00 -> $91.00LowView Rating Details
5/28/2017Evercore ISIReiterated RatingOutperform$88.50 -> $91.00LowView Rating Details
5/26/2017CIBCReiterated RatingBuyLowView Rating Details
5/25/2017Needham & Company LLCReiterated RatingBuy -> Buy$91.00 -> $95.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$87.00LowView Rating Details
4/20/2017Northland SecuritiesReiterated RatingHold$80.00MediumView Rating Details
3/20/2017BTIG ResearchReiterated RatingNeutralLowView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$80.00 -> $85.00N/AView Rating Details
2/22/2017WedbushReiterated RatingNeutral$85.00N/AView Rating Details
1/3/2017Bank of America CorporationDowngradeBuy -> Neutral$78.00N/AView Rating Details
1/3/2017J P Morgan Chase & CoDowngradeOverweight -> Neutral$84.00 -> $79.00N/AView Rating Details
8/25/2016Credit Suisse GroupReiterated RatingOutperform$92.00N/AView Rating Details
8/23/2016Citigroup Inc.Initiated CoverageBuy$63.98 -> $102.00N/AView Rating Details
6/20/2016ArgusReiterated RatingHold -> HoldN/AView Rating Details
6/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$93.00 -> $94.00N/AView Rating Details
6/13/2016SunTrust Banks, Inc.Boost Price TargetBuy$93.00 -> $98.00N/AView Rating Details
6/8/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$86.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Medtronic PLC (NYSE:MDT)
Earnings by Quarter for Medtronic PLC (NYSE:MDT)
Earnings History by Quarter for Medtronic PLC (NYSE MDT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2017$1.07N/AView Earnings Details
8/22/20177/31/2017$1.08$1.12$7.44 billion$7.39 billionViewN/AView Earnings Details
5/25/2017Q4 17$1.31$1.33$7.86 billion$7.92 billionViewN/AView Earnings Details
2/21/20171/31/2017$1.11$1.12$7.22 billion$7.28 billionViewListenView Earnings Details
11/22/2016Q217$1.11$1.12$7.46 billion$7.35 billionViewListenView Earnings Details
8/25/2016Q117$1.01$1.03$7.17 billion$7.20 billionViewListenView Earnings Details
5/31/2016Q416$1.26$1.27$7.49 billion$7.57 billionViewListenView Earnings Details
3/1/2016Q316$1.06$1.06$6.99 billion$6.93 billionViewListenView Earnings Details
12/3/2015Q216$1.00$1.03$7.08 billion$7.06 billionViewListenView Earnings Details
9/3/2015Q116$1.01$1.02$7.03 billion$7.27 billionViewListenView Earnings Details
6/2/2015Q415$1.11$1.16$7.18 billion$7.30 billionViewListenView Earnings Details
2/17/2015Q3$0.97$1.01$4.25 million$4.32 millionViewListenView Earnings Details
11/18/2014Q2$0.96$0.96$4.37 million$4.40 millionViewListenView Earnings Details
8/19/2014Q115$0.92$0.93$4.25 billion$4.27 billionViewListenView Earnings Details
5/20/2014Q414$1.12$1.12$4.58 billion$4.60 billionViewListenView Earnings Details
2/18/2014Q314$0.91$0.91$4.15 billion$4.20 billionViewListenView Earnings Details
11/19/2013Q214$0.90$0.91$4.18 billion$4.20 billionViewListenView Earnings Details
8/20/2013Q1 2014$0.88$0.88$4.11 billion$4.10 billionViewListenView Earnings Details
5/21/2013Q4 2013$1.03$1.10$4.39 billion$4.50 billionViewListenView Earnings Details
2/19/2013Q3 2013$0.91$0.93$4.03 billion$4.03 billionViewListenView Earnings Details
11/20/20120.88$0.88$4.10 billionViewN/AView Earnings Details
8/21/2012$0.85$0.85ViewN/AView Earnings Details
5/22/2012$0.98$0.99ViewN/AView Earnings Details
2/21/2012$0.84$0.88ViewN/AView Earnings Details
11/22/2011$0.82$0.84ViewN/AView Earnings Details
8/23/2011$0.79$0.79ViewN/AView Earnings Details
5/24/2011$0.93$0.90ViewN/AView Earnings Details
2/22/2011$0.84$0.86ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medtronic PLC (NYSE:MDT)
2017 EPS Consensus Estimate: $4.62
2018 EPS Consensus Estimate: $4.79
2019 EPS Consensus Estimate: $5.22
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20177$1.00$1.15$1.03
Q2 20177$1.10$1.37$1.16
Q3 20177$1.10$1.15$1.12
Q4 20177$1.29$1.34$1.31
Q1 20186$1.07$1.15$1.10
Q2 20187$1.03$1.20$1.10
Q3 20187$1.16$1.24$1.19
Q4 20187$1.35$1.46$1.41
Q1 20193$1.12$1.20$1.16
Q2 20193$1.12$1.26$1.20
Q3 20193$1.29$1.34$1.31
Q4 20193$1.52$1.57$1.55
(Data provided by Zacks Investment Research)


Current Dividend Information for Medtronic PLC (NYSE:MDT)
Next Dividend:10/20/2017
Annual Dividend:$1.84
Dividend Yield:2.31%
Dividend Growth:24.20% (3 Year Average)
Payout Ratio:61.95% (Trailing 12 Months of Earnings)
38.57% (Based on This Year's Estimates)
35.73% (Based on Next Year's Estimates)
Track Record:39 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Medtronic PLC (NYSE:MDT)

Dividend History by Quarter for Medtronic PLC (NYSE MDT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Medtronic PLC (NYSE:MDT)
Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 80.63%
Insider Trades by Quarter for Medtronic PLC (NYSE:MDT)
Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)
Insider Trades by Quarter for Medtronic PLC (NYSE:MDT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Omar IshrakCEOSell140,407$81.63$11,461,423.41View SEC Filing  
7/17/2017Bryan C. HansonEVPSell12,000$88.57$1,062,840.00View SEC Filing  
6/21/2017Richard H AndersonDirectorBuy5,600$88.90$497,840.00View SEC Filing  
3/20/2017Hoedt Rob TenEVPSell50,757$81.58$4,140,756.06View SEC Filing  
3/15/2017Omar IshrakCEOSell95,000$82.82$7,867,900.00View SEC Filing  
3/2/2017Hooman HakamiEVPSell52,316$82.33$4,307,176.28View SEC Filing  
12/13/2016Robert C. PozenDirectorBuy13,660$73.21$1,000,048.60View SEC Filing  
11/23/2016James T. LenehanDirectorBuy2,000$73.27$146,540.00View SEC Filing  
9/27/2016Richard KuntzVPSell17,141$86.70$1,486,124.70View SEC Filing  
9/26/2016Richard KuntzVPSell25,199$86.67$2,183,997.33View SEC Filing  
9/15/2016Kendall J. PowellDirectorSell7,907$85.45$675,653.15View SEC Filing  
9/15/2016Omar IshrakCEOSell61,925$84.93$5,259,290.25View SEC Filing  
8/29/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/26/2016Bryan C HansonEVPSell15,000$87.00$1,305,000.00View SEC Filing  
7/15/2016Geoffrey MarthaEVPSell3,766$88.26$332,387.16View SEC Filing  
7/13/2016Gary Lee EllisEVPSell35,495$88.64$3,146,276.80View SEC Filing  
7/13/2016Shirley A JacksonDirectorSell2,104$88.64$186,498.56View SEC Filing  
7/6/2016Carol A. SurfaceSVPSell9,787$87.08$852,251.96View SEC Filing  
7/5/2016Bryan C. HansonEVPSell15,272$87.11$1,330,343.92View SEC Filing  
6/3/2016Richard KuntzVPSell49,905$82.60$4,122,153.00View SEC Filing  
4/1/2016Richard KuntzVPSell4,000$75.22$300,880.00View SEC Filing  
3/18/2016Shirley A JacksonDirectorSell1,238$75.60$93,592.80View SEC Filing  
3/17/2016Omar IshrakCEOSell23,799$76.15$1,812,293.85View SEC Filing  
3/4/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
2/5/2016Bryan C. HansonEVPSell5,000$76.14$380,700.00View SEC Filing  
1/8/2016Bryan C HansonEVPSell5,000$75.00$375,000.00View SEC Filing  
12/4/2015Richard KuntzVPSell13,715$78.06$1,070,592.90View SEC Filing  
9/15/2015Omar IshrakCEOSell20,000$69.43$1,388,600.00View SEC Filing  
7/14/2015Carol A SurfaceSVPSell13,722$75.83$1,040,539.26View SEC Filing  
4/6/2015Richard KuntzVPSell31,768$77.39$2,458,525.52View SEC Filing  
3/25/2015Gary Lee EllisCFOSell43,183$77.81$3,360,069.23View SEC Filing  
3/13/2015Omar IshrakCEOSell20,000$76.24$1,524,800.00View SEC Filing  
2/19/2015Christopher J OconnellEVPSell50,361$78.22$3,939,237.42View SEC Filing  
12/19/2014Richard KuntzVPSell12,855$74.54$958,211.70View SEC Filing  
12/2/2014Shirley A JacksonDirectorSell1,102$74.43$82,021.86View SEC Filing  
11/28/2014Christopher J OconnellEVPSell42,921$73.95$3,174,007.95View SEC Filing  
10/6/2014Christopher J OconnellEVPSell15,388$64.98$999,912.24View SEC Filing  
8/26/2014Christopher J OconnellEVPSell28,000$63.57$1,779,960.00View SEC Filing  
8/26/2014Shirley A JacksonDirectorSell2,769$63.66$176,274.54View SEC Filing  
4/17/2014Catherine SzymanVPSell29,420$58.79$1,729,601.80View SEC Filing  
4/9/2014Richard KuntzVPSell2,512$60.98$153,181.76View SEC Filing  
4/1/2014Gary Lee EllisCFOSell4,246$61.48$261,044.08View SEC Filing  
3/28/2014Christopher OconnellEVPSell1,982$60.39$119,692.98View SEC Filing  
3/20/2014Catherine SzymanVPSell14,979$59.57$892,299.03View SEC Filing  
3/14/2014Omar IshrakCEOSell10,000$59.12$591,200.00View SEC Filing  
3/10/2014Neil AyotteVPSell1,845$59.64$110,035.80View SEC Filing  
12/4/2013Neil AyotteVPSell1,729$57.14$98,795.06View SEC Filing  
9/13/2013Omar IshrakCEOSell10,000$53.58$535,800.00View SEC Filing  
8/26/2013Catherine SzymanVPSell56,998$52.60$2,998,094.80View SEC Filing  
8/22/2013H James DallasVPSell32,332$53.19$1,719,739.08View SEC Filing  
8/21/2013H James DallasVPSell36,256$52.82$1,915,041.92View SEC Filing  
8/21/2013Shirley JacksonDirectorSell8,033$52.84$424,463.72View SEC Filing  
7/11/2013Christopher J OconnellEVPSell30,429$52.92$1,610,302.68View SEC Filing  
7/11/2013Gary Lee EllisCFOSell32,602$53.62$1,748,119.24View SEC Filing  
7/11/2013H James DallasVPSell69,889$53.72$3,754,437.08View SEC Filing  
7/1/2013H James DallasVPSell20,579$52.10$1,072,165.90View SEC Filing  
6/26/2013D Cameron FindlayVPSell75,042$52.20$3,917,192.40View SEC Filing  
6/19/2013H James DallasVPSell94,117$52.74$4,963,730.58View SEC Filing  
5/22/2013Richard H AndersonDirectorBuy4,800$52.32$251,136.00View SEC Filing  
5/10/2013Jack W SchulerDirectorSell34,230$48.24$1,651,255.20View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Medtronic PLC (NYSE:MDT)
Latest Headlines for Medtronic PLC (NYSE:MDT)
DateHeadline logoMedtronic (MDT) Down 2.7% Since Earnings Report: Can It Rebound? - September 23 at 8:08 PM logoMedtronic (MDT) Down 2.7% Since Earnings Report: Can It Rebound? - Nasdaq - September 23 at 8:07 AM logoMedtronic (MDT) Reports Clinical Study to Evaluate the CoreValve ... - - September 22 at 5:04 AM logoMedtronic Plc (MDT) Chairman & CEO Omar Ishrak Sold $11.5 million of Shares - Nasdaq - September 20 at 6:11 AM logoArch Therapeutics (ARTH) vs. Medtronic PLC (MDT) Head to Head Comparison - September 19 at 6:10 PM logoMedtronic launches Intellis SCS implant for chronic pain in U.S. - September 19 at 2:18 AM logoOmar Ishrak Sells 140,407 Shares of Medtronic PLC (MDT) Stock - September 18 at 10:26 PM logoMedtronic Announces FDA Approval and US Launch of Next Generation Spinal Cord Stimulator for Chronic Pain ... - Nasdaq - September 18 at 9:15 PM logoMedtronic PLC (MDT) Downgraded by Zacks Investment Research to Sell - September 18 at 12:56 AM logoMedtronic PLC (MDT) Expected to Announce Quarterly Sales of $7.09 Billion - September 16 at 1:30 PM logoMedtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm - September 15 at 6:23 AM logoMedtronic Looks Vulnerable to a Bigger Decline - September 15 at 6:23 AM logoNew Five-Year Gender Subset Data from the Medtronic Engage Registry Presented in VIVA Late Breaking Trials - September 15 at 6:23 AM logoMedtronic PLC (MDT) and Arch Therapeutics (ARTH) Head to Head Survey - September 14 at 2:26 PM logo$1.07 EPS Expected for Medtronic PLC (MDT) This Quarter - September 14 at 6:30 AM logoMedtronic (MDT) Begins Product Recall, Diabetes Group a Drag - Nasdaq - September 13 at 6:26 AM logoMedtronic recalls diabetes infusion sets given risk of over-delivery of ... - MarketWatch - September 12 at 1:04 AM logoMedtronic PLC (MDT) Upgraded to Hold at Zacks Investment Research - September 10 at 6:34 PM logoIs a Med-Tech Marriage in Mazor Robotics' Future? - September 10 at 5:37 AM logoMedtronic (MDT) Reports Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon - September 9 at 8:12 PM logoMedtronic PLC (MDT) versus Arch Therapeutics (ARTH) Financial Analysis - September 9 at 6:46 PM logoMedtronic PLC (MDT) & Arch Therapeutics (ARTH) Financial Review - September 9 at 2:08 PM logoMedtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon - GlobeNewswire (press release) - September 9 at 6:07 AM logoMedtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon - September 9 at 6:07 AM logoMedtronic's IN.PACT DCB OK'd in Japan - September 8 at 9:47 AM logoMedtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level - Nasdaq - September 7 at 1:32 AM logoRoundtable: 1 Stock Retirees Should Consider - September 5 at 7:07 PM logoMedtronic Launches Long Term Clinical Study Program of INFUSE Bone Graft in Two Common Spine Procedures: PLF and TLIF - September 5 at 5:05 PM logoMedtronic’s Downward Revision to Its Fiscal 2018 Guidance - September 5 at 5:05 PM logoMedtronic EVP & CVG President Mike Coyle to Speak at Wells Fargo Healthcare Conference - September 5 at 5:04 PM logoMedtronic: Is It Worth It? - Seeking Alpha - September 5 at 5:34 AM logoWhat’s behind Medtronic’s Accelerating Margin Expansion? - September 4 at 7:28 PM logoMedtronic PLC (MDT) Given Average Recommendation of "Hold" by Brokerages - September 2 at 6:52 PM logoFeatured Company News - Strategic Partnership Between Mazor Robotics and Medtronic Moves to Next Level Before Schedule - September 2 at 6:11 AM logoMedtronic’s Emerging Market Position and Opportunities for Fiscal 2018 - September 2 at 6:11 AM logoDid June’s IT Disruption Hurt Medtronic’s Sales in Fiscal 1Q18? - September 1 at 4:03 AM logoHow Medtronic Is Accelerating Its Economic Value Growth Strategy - September 1 at 4:03 AM logoEarnings Highlights: Medtronic’s Fiscal 1Q18 Results - August 31 at 7:08 AM logoMedtronic PLC to Issue Quarterly Dividend of $0.46 (MDT) - August 29 at 10:35 AM logoTechnical Snapshots for These Medical Equipment Stocks -- Abbott Labs, Boston Scientific, Edwards Lifesciences, and Medtronic - August 28 at 3:21 PM logoMedtronic Plans for Renal Denervation Pivotal Trial After New Study Shows Significant Blood Pressure Reductions - August 28 at 3:21 PM logoBarron's Picks And Pans: Medtronic, Yum China, PayPal And More - Benzinga - August 28 at 5:35 AM logoEquities Analysts Issue Forecasts for Medtronic PLC's Q2 2018 Earnings (MDT) - August 28 at 5:10 AM logoBarron's Picks And Pans: Medtronic, Yum China, PayPal And More - August 28 at 12:34 AM logo$1.04 Earnings Per Share Expected for Medtronic PLC (MDT) This Quarter - August 26 at 8:18 PM logoMedtronic PLC (MDT) Lowered to "Sell" at BidaskClub - August 26 at 3:02 PM logoMedtronic (MDT) Presents At CFA Society of Minnesota 6th Annual Intellisight Conference - Slideshow - August 26 at 7:04 AM logoMedtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2018 - August 26 at 7:04 AM logo[$$] Medtronic: Healthy and Getting Healthier - August 26 at 7:04 AM logoMedtronic PLC (MDT) Downgraded to Sell at Zacks Investment Research - August 25 at 2:56 PM



Medtronic PLC (MDT) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff